Exploring the role of enzalutamide in combination with radiation therapy: An in vitro study
Articolo
Data di Pubblicazione:
2018
Abstract:
BACKGROUND/AIM:
Androgen receptor plays a key role in prostate cancer development and is a causative agent of its radio-resistance. The present study investigated the potential radio-sensitizing effect of enzalutamide, a second-generation anti-androgen, in human prostate cancer cells.
MATERIALS AND METHODS:
The radio-sensitizing effect of enzalutamide was assessed in the androgen-dependent LNCaP cells and the androgen-independent PC3 cells by clonogenic assay and γ-H2AX assay.
RESULTS:
Enzalutamide-treated LNCaP cells showed a significant decrease of cell survival at all radiation doses tested. An increased number of γ-H2AX-positive nuclei was observed, suggesting a possible impairment of the DNA repair machinery. Conversely, enzalutamide did not exhibit a significant radio-sensitizing effect on PC3 cells.
CONCLUSION:
The combination of enzalutamide with ionizing radiation significantly improves radio-sensitivity of hormone-dependent LNCaP cells. Translated in the clinical practice, our results may help to find additional strategies to improve effectiveness of radiotherapy.
Androgen receptor plays a key role in prostate cancer development and is a causative agent of its radio-resistance. The present study investigated the potential radio-sensitizing effect of enzalutamide, a second-generation anti-androgen, in human prostate cancer cells.
MATERIALS AND METHODS:
The radio-sensitizing effect of enzalutamide was assessed in the androgen-dependent LNCaP cells and the androgen-independent PC3 cells by clonogenic assay and γ-H2AX assay.
RESULTS:
Enzalutamide-treated LNCaP cells showed a significant decrease of cell survival at all radiation doses tested. An increased number of γ-H2AX-positive nuclei was observed, suggesting a possible impairment of the DNA repair machinery. Conversely, enzalutamide did not exhibit a significant radio-sensitizing effect on PC3 cells.
CONCLUSION:
The combination of enzalutamide with ionizing radiation significantly improves radio-sensitivity of hormone-dependent LNCaP cells. Translated in the clinical practice, our results may help to find additional strategies to improve effectiveness of radiotherapy.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Androgen receptor; Enzalutamide; Ionizing radiation; Prostate cancer; Γ-H2AX; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Histones; Humans; Male; Phenylthiohydantoin; Prostatic Neoplasms; Radiation-Sensitizing Agents; Oncology; Cancer Research
Elenco autori:
Triggiani, Luca; Colosini, Antonella; Buglione, Michela; Pasinetti, Nadia; Orizio, Flavia; Bardoscia, Lilia; Borghetti, Paolo; Maddalo, Marta; Spiazzi, Luigi; Magrini, Stefano Maria; Bresciani, Roberto
Link alla scheda completa:
Pubblicato in: